Here are my questions so far in no particular order. I hope I get to ask them all.
Anavex Shareholders Meeting Questions
What would a fair market value be if we showed positive improvements in any of the 3 indications?
How should we view an extension in any of these trials? Is that built into the trial or does it have to be requested by the patients or doctors running the trials?
What type of partnering are you interested in, indication partner or just manufacturing and distribution?
Are we on the short list for ACTC ( Alzheimers Clinical Trials Consortium ) ? When will the decisions be made and the projected start for funding?
Can we get an update as to how the original patients who have been taking 2-73 long term (148 weeks ) responding? Still improving or remaining stable?
Our new CMO made a comment on new data regarding the Gut Bio that will be discussed at the next scientific conference. Any dates for this? Anything you can tell us about it now?
What is the company doing to attract a good stable group of institutional investors that understand the science? Certainly that will help stabilize the price and hopefully reduce the games being played by constant short attacks.
Who do you see as your main competitors for each of the 3 indications that are in trials and where do you believe we stand in comparison?
What has been the major issues with the FDA approving a USA arm for the Alzheimer's trial.
Assuming success in any one of the 3 trials, what is the earliest time frame can you see the product coming to market in ANY part of the World?
When will Anavex 3-71 go into a P1 trial?
What are the timeframes for adding new indications for 2-73?
What is the reason for the $1M for a large scale manufacturing run for 2-73 for commercial use. This implies that you are getting ready to sell the product. Isn't this putting the cart before the horse? Also, $1M seems like a small dollar amount for large scale manufacturing.
We recently joined the ERP Biomarker Qualification Consortium to target Schizophrenia. I have 2 questions for you. How did we get involved with this Consortium? Were we asked to join? Were we one of the members that formed the group? Question 2, in your pipeline slides there is nothing on the schedule for Schizophrenia. Can you give us some color as to what this means and what pipeline drug fits into this area?
You have spoken about partnerships for the better part of the last 4 years yet we have not seen anything materialize. Can you give a flavor on where you stand on partnering and or out licensing any of our drugs in the pipeline?
Can you guarantee us that the Blank Check will not be used for anything other than to prevent an unwanted acquisition?
Assuming that Anavex 2-73 works, is it the company's intent to become a big pharmaceutical company or is their an exit plan?
AI
Market Data 
Markets 
